in Österreich, Stand 1.2.2023

NeoADAURA: A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT04351555

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
https://www.clinicaltrials.gov/ct2/show/NCT04819100

HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
https://clinicaltrials.gov/ct2/show/NCT03334617

Evoke-01: Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
https://clinicaltrials.gov/ct2/show/NCT05089734

KEYVIBE-007: A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT05226598

Exclaim-2: A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
https://www.clinicaltrials.gov/ct2/show/NCT04129502

Krystal-7: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
https://clinicaltrials.gov/ct2/show/NCT04613596

DESTINY-Lung04: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations
https://clinicaltrials.gov/ct2/show/NCT05048797

M18-868: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met+, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT04928846

KEYNOTE-B99: A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer https://clinicaltrials.gov/ct2/show/NCT04924101

KEYVIBE-008: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT05224141

KEYNOTE-B98: A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy
https://clinicaltrials.gov/ct2/show/NCT04938817

TelisoMET (AbbVie): A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared
to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT04928846?term=m18-868&draw=2&rank=1

Landsteiner Lung Cancer Research Platform (LALUCA) – A prospective analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Patientenpopulation: alle Patientinnen und Patientin mit Lungenkrebs
Zeitrahmen: seit 2020, open end

CODEBREAK 202: Phase 3, First line, Pembro + Platin-Dublette (SoC) versus Sotorasib + Platin-Dublette bei Patienten mit KRAS G12C und PDL-1 <1%
Ansprechpartner: OA Dr. Hackner Klaus, klaus.hackner@krems.lknoe.at

DELLphi 304: AMG 757- Tarlatamab- 20210004 : A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line Chemotherapy
Ansprechpartner: OA Dr. Sabin Handzhiev, sabin.handzhiev@krems.lknoe.at

SPACE: Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide
Start: Okt. 2020
Ansprechpartner: OA Dr. Klaus Hackner, klaus.hackner@krems.lknoe.at

AMG 757 (DeLphi-301): A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757
in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Start: Feb. 2022
Ansprechpartner: OA Dr. Sabin Handzhiev, sabin.handzhiev@krems.lknoe.at

KEYNOTE-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT03924869

SKYSCRAPER 03: A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
https://clinicaltrials.gov/ct2/show/NCT04513925

TREASURE: Thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease: a randomized, open-label, multicenter phase II study https://www.clinicaltrials.gov/ct2/show/NCT04462276

ImReal MO40653: A non-interventional, multi-centre, multiple cohort study to investigate the outcomes and safety of atezolizumab under real-life conditions in patients treated in routine clinical practice.

KontRASt-06: An open-label phase II trial evaluating the activity and safety ofJDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PDL1 expression < 1% or a PD-L1 expression < 1% and an STK11 co-mutation.
https://classic.clinicaltrials.gov/ct2/show/NCT05445843

Sotorasib AMGEN: A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects with Stage IV or advanced Stage IIIB/C nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and positive for KRAS p.G12C (CodeBreaK 202)
https://classic.clinicaltrials.gov/ct2/show/NCT05920356

Tropion Lung 08: A Randomized, Open-label, Phase 3 Trial of Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab vs Pembrolizumab alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS >50%) Non-small Gell Lung Cancer without actionable genomic Alterations
https://classic.clinicaltrials.gov/ct2/show/NCT05215340

Tropion Lung 07: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without actionable genomic Alterations (TROPION-LUNG07)”
https://classic.clinicaltrials.gov/ct2/show/NCT05555732

GS-US-626-6216 – Star-121: A Randomized, Open-Label, Phase 3 Study to evaluate Zimberelimab and Domvanalimab in combination with Chemotherapy versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non–Small Cell Lung Cancer with No epidermal growth factor receptor or anaplastic Lymphoma kinase genomic tumor Aberrations
https://classic.clinicaltrials.gov/ct2/show/NCT05502237

Mirati Krystal7: A Phase 2 Trial of MRTX849 Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab plus Chemotherapy in Patients with Advanced Non-Small KRAS G12C Mutations
https://classic.clinicaltrials.gov/ct2/show/NCT04613596

MO42720 – Origama: Interventional platform Study investigating the impact of digital health solutions on health outcomes and health-care resource utilization in participants receiving systemic treatment in clinical practice (ORIGAMA)

Brigatinib 5007 – PASS: A Cohort Study to Describe the Occurrence of Early-Onset Pulmonary Events in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Treated with Brigatinib: A Post-

MO42122 ReAlec: A multicenter noninterventional cohort study to evaluate the real world clinical managements and outcomes of patients diagnosed with ALK positive advanced NSCLC treated with Alectinib (Realec)

AMG 757 (TARLATAMAB) – A Bite molecule+: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination With AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
https://www.clinicaltrials.gov/ct2/show/NCT04885998

INN-WOP1, Phase II:  Neoadjuvante Window-Of-Opportunity-Studie zur Kurzzeittherapie mit Pembrolizumab/Lenvatinib vor OP eines NSCLC in frühen Stadien. Postoperativ Pembrolizumab für 1 Jahr. Akademische, monozentrische Studie. Nach erfolgtem Amendment können Patient*innen sowohl vor als auch nach erfolgter histologischer Diagnosesicherung eingeschlossen werden.

Keynote 867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT03924869

Keyvibe, Phase III: Metast. NSCLC, First-Line-Therapie; Randomisierung zwischen CTX + Pembrolizumab vs. CTX + Pembrolizumab + Vibostolimab (Anti-TIGIT-Antikörper)

Destiny Lung 04: First Line Therapie mestast. NSCLC, Her2-mutiert. Randomisierung zwischen CTX+ Immuntherapie vs. Trastuzumab-Deruxtecan